We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Gene Activation in Tuberculosis Counters Host Immune Response

By Biotechdaily staff writers
Posted on 05 Apr 2004
Researchers have adapted high-speed gene chip microarray technology to study the pattern of gene activation in Mycobacterium tuberculosis cells growing in normal mice, immune-deficient mice, and in culture.

Investigators at the University of Texas Southwestern Medical Center (Dallas, USA) spent more than two years developing a protocol that allowed high-throughput analysis of genes that were expressed in a pathogent extracted from an infected animal, rather than simply grown in culture. More...


Using this tool they found that M tuberculosis cells removed from mice 21 days after infection showed activity in a set of 67 genes that did not function in cells grown in immune-deficient mice or in culture. The activity of these genes was thought to be required for avoidance of the host's immune response. The finding that bacteria from immune deficient mice displayed the same lack of gene activity as those from culture calls into question the use of immune-deficient mice for drug development studies. These results were published in the March 18, 2004, online issue of the Proceedings of the [U.S.] National Academy of Sciences.

"This is an example of how the high-throughput system is a new avenue to study a variety of pathogens and how they affect living hosts,” said senior author Dr. Stephen Albert Johnston, director of the Center for Biological Inventions at the University of Texas Southwestern Medical Center. "We see it as a tool for vaccine and drug development against disease and the threat of biological weapons. By identifying the genes that cause disease progression in vivo, we can begin to piece together the knowledge that will allow us to discover better targets for drug therapies.”




Related Links:
UT Southwestern Medical Center

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.